Key Takeaways Differentiated obesity pipeline, strategic partnerships, and robust real-world efficacy set Zealand Pharma to outpace market growth and competitor expectations in metabolic diseases. Capital-efficient R&D and broad program scope position the company for rapid label expansion, high patient adherence, and durable, outsized recurring revenues.Read more
Key Takeaways Major data from obesity drug trials and new industry alliances position the company for expanded future revenues, lowered commercialization risks, and greater global market access. Strong financial reserves enable self-funded innovation and product launches, with pipeline diversification aligning well with emerging trends in obesity treatment.Read more
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.
